Protalix BioTherapeutics/$PLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Protalix BioTherapeutics
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Ticker
$PLX
Sector
Primary listing
AMEX
Employees
226
Headquarters
Website
PLX Metrics
BasicAdvanced
$174M
-
-$0.08
-0.23
-
Price and volume
Market cap
$174M
Beta
-0.23
52-week high
$3.19
52-week low
$1.32
Average daily volume
1.3M
Financial strength
Current ratio
2.514
Quick ratio
1.475
Long term debt to equity
14.383
Total debt to equity
17.253
Interest coverage (TTM)
-4.62%
Profitability
EBITDA (TTM)
-4.035
Gross margin (TTM)
13.01%
Net profit margin (TTM)
-12.52%
Operating margin (TTM)
-10.43%
Effective tax rate (TTM)
-17.76%
Revenue per employee (TTM)
$230,000
Management effectiveness
Return on assets (TTM)
-4.41%
Return on equity (TTM)
-14.44%
Valuation
Price to revenue (TTM)
3.217
Price to book
3.6
Price to tangible book (TTM)
3.6
Price to free cash flow (TTM)
-12.447
Free cash flow yield (TTM)
-8.03%
Free cash flow per share (TTM)
-0.174
Growth
Revenue change (TTM)
-1.23%
Earnings per share change (TTM)
-329.39%
3-year revenue growth (CAGR)
3.45%
10-year revenue growth (CAGR)
28.30%
3-year earnings per share growth (CAGR)
-35.27%
10-year earnings per share growth (CAGR)
-34.86%
What the Analysts think about PLX
Analyst ratings (Buy, Hold, Sell) for Protalix BioTherapeutics stock.
PLX Financial Performance
Revenues and expenses
PLX Earnings Performance
Company profitability
PLX News
AllArticlesVideos
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
Proactive Investors·1 week ago
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
Proactive Investors·2 weeks ago
Protalix wins EU panel backing for expanded dosing of Fabry disease drug
Proactive Investors·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Protalix BioTherapeutics stock?
Protalix BioTherapeutics (PLX) has a market cap of $174M as of March 26, 2026.
What is the P/E ratio for Protalix BioTherapeutics stock?
The price to earnings (P/E) ratio for Protalix BioTherapeutics (PLX) stock is 0 as of March 26, 2026.
Does Protalix BioTherapeutics stock pay dividends?
No, Protalix BioTherapeutics (PLX) stock does not pay dividends to its shareholders as of March 26, 2026.
When is the next Protalix BioTherapeutics dividend payment date?
Protalix BioTherapeutics (PLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Protalix BioTherapeutics?
Protalix BioTherapeutics (PLX) has a beta rating of -0.23. This means that it has an inverse relation to market volatility.